{"id":"NCT03208933","sponsor":"Hoffmann-La Roche","briefTitle":"Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).","officialTitle":"Local Open-label Multicenter Study to Assess the Effectiveness of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis in Russian Clinical Practice","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-23","primaryCompletion":"2019-11-13","completion":"2019-11-13","firstPosted":"2017-07-06","resultsPosted":"2020-11-20","lastUpdate":"2020-11-20"},"enrollment":60,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Pulmonary Fibrosis"],"interventions":[{"type":"DRUG","name":"Pirfenidone","otherNames":["Esbriet, RO0220912"]}],"arms":[{"label":"Pirfenidone","type":"EXPERIMENTAL"}],"summary":"This study is a national, multicenter, interventional, non-randomized, non-controlled, open-label study to assess the effectiveness of pirfenidone in participants with IPF in Russian clinical practice.","primaryOutcome":{"measure":"Change From Baseline to Week 26 in Absolute Millilitre (mL) Forced Vital Capacity (FVC)","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"Pirfenidone","deltaMin":128.78,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":18},"locations":{"siteCount":11,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":60},"commonTop":["Nausea","Decreased appetite","Dyspepsia","Vomiting","Diarrhoea"]}}